A recent study from Taiwan revealed a concerning link between newly detected diabetes mellitus and a higher prevalence of ...
Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Discover how regular exercise can strengthen your heart, regulate blood sugar and lower heart disease risk for those with ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Dialysis Centers used data from the Centers for Disease Control and Prevention to examine the prevalence of chronic diseases ...
News Medical on MSN7h
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial showsSotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback